Beam Therapeutics
BEAM Mid CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
Beam Therapeutics Stock at a Glance
Beam Therapeutics (BEAM) is currently trading at 26,19 € with a market capitalization of 2,7 Mrd. €. The 52-week range spans from 13,09 € to 31,08 €; the current price is 15.8% below the yearly high. Year-over-year revenue growth stands at +279.5%.
💰 Dividendo
Beam Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
15 analysts rate Beam Therapeutics (BEAM) on consensus: None. The average price target is 43,67 €, implying +66.78% from the current price. Analyst price targets range from 22,18 € to 68,24 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Strong revenue growth of 279.5% YoY
- Solid balance sheet with low debt (D/E 12.45)
- –Currently unprofitable
- –High volatility (Beta 2.19)
- –High short interest (33.53%)
- –Negative free cash flow
Panoramica Tecnica
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profilo di Rischio
The data points to above-average price swings, elevated short interest (33.53%).
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy Beam Therapeutics?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
